Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Josh Jennings is an analyst at Morgan Stanley. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/08/2025
Buy Now | Get Alert | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
11/10/2023 | DCBO | Buy Now | Docebo | $33.52 | 58.11% | Josh Jennings69% | $49 → $53 | Maintains | Overweight | Get Alert |
08/18/2023 | DCBO | Buy Now | Docebo | $33.52 | 46.18% | Josh Jennings69% | $40 → $49 | Upgrade | Equal-Weight → Overweight | Get Alert |
08/11/2023 | DCBO | Buy Now | Docebo | $33.52 | 19.33% | Josh Jennings69% | $37 → $40 | Maintains | Equal-Weight | Get Alert |
08/09/2023 | PODD | Buy Now | Insulet | $258.85 | 15.9% | Josh Jennings69% | $350 → $300 | Maintains | Outperform | Get Alert |
05/12/2023 | DCBO | Buy Now | Docebo | $33.52 | 10.38% | Josh Jennings69% | $39 → $37 | Maintains | Equal-Weight | Get Alert |
03/10/2023 | DCBO | Buy Now | Docebo | $33.52 | 16.35% | Josh Jennings69% | $36 → $39 | Maintains | Equal-Weight | Get Alert |
08/22/2022 | PODD | Buy Now | Insulet | $258.85 | 19.76% | Josh Jennings69% | → $310 | Maintains | Outperform | Get Alert |
03/04/2022 | AZYO | Buy Now | Aziyo Biologics | — | — | Josh Jennings69% | $15 → $13 | Maintains | Outperform | Get Alert |
07/21/2021 | PODD | Buy Now | Insulet | $258.85 | 19.76% | Josh Jennings69% | $285 → $310 | Assumes | Outperform → Outperform | Get Alert |
06/21/2021 | BFLY | Buy Now | Butterfly Network | $2.28 | 777.19% | Josh Jennings69% | → $20 | Initiates | → Outperform | Get Alert |
09/28/2017 | MDWD | Buy Now | MediWound | $17.60 | -48.86% | Josh Jennings69% | → $9 | Initiates | → Outperform | Get Alert |
06/07/2017 | CTSO | Buy Now | CytoSorbents | $0.89 | 686.52% | Josh Jennings69% | → $7 | Initiates | → Outperform | Get Alert |
12/07/2016 | EW | Buy Now | Edwards Lifesciences | $75.33 | 59.3% | Josh Jennings69% | $130 → $120 | Maintains | Outperform | Get Alert |
04/27/2016 | EW | Buy Now | Edwards Lifesciences | $75.33 | 59.3% | Josh Jennings69% | $105 → $120 | Maintains | Outperform | Get Alert |
10/09/2015 | EW | Buy Now | Edwards Lifesciences | $75.33 | 145.59% | Josh Jennings69% | → $185 | Initiates | → Outperform | Get Alert |